Congratulations to Richard Macaulay on his well-attended presentation “The New SMC-Ultra-Orphan Pathway: HTA Best Practice for Very Rare Diseases?” at Virtual ISPOR 2021. In case you missed this insightful presentation, it is now available on-demand.
Did you miss PRECISIONadvisors at Virtual ISPOR 2021? Check out all of our presentations and download our posters from the conference here.
PRECISIONadvisor's Director David Carr recently attended World Orphan Drug Conference 2021, and found two panels particularly insightful: "Outlook on European market access strategies for rare diseases" and "Pricing & reimbursement for rare diseases in the United States." In case you couldn't attend, David noted the key takeaways of each presentation.
Did you miss PRECISIONadvisor's Richard Macaulay present "The Future of Innovative Reimbursement for Cell & Gene Therapies" at World EPA Congress 2021?
Miss ASGCT 2021? Check out this cell therapy panel discussion you won't want to miss! Precision experts David Parker, Alex Grosvenor and Megan Liles, and Project Farma's John Khoury join biotech executives on the front lines of development for "Considerations for the Clinical Development of Cell & Gene Therapies." Part 1 - Cell Therapy.
Congratulations to PRECISIONadvisors and PRECISIONheor for presenting more than a dozen posters and panels at Virtual ISPOR Europe 2020, 16 - 19 November, 2020.
Congratulations to Precision Medicine Group Co-Founder and CEO Mark Clein on his moderated Point: Counterpoint panel at this year’s HLTH Conference.
What are the most important market dynamics to ensure the success of your gene therapy?
Hosted by the AMCP in collaboration with Precision Xtract, this unique half-day interactive training program will be led by Precision’s Stephen Carter.
Precision is excited to be in Copenhagen, November 2nd - 6th! Be sure to catch our scientific presentations taking place throughout the conference and meet our experts.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
